Dai­ichi ditch­es Nek­tar fol­low­ing can­cer drug flop

Phar­ma gi­ant Dai­ichi Sankyo is bail­ing on its col­lab­o­ra­tion with Nek­tar Ther­a­peu­tics $NK­TR — and de­mand­ing a $12.5 mil­lion re­fund — fol­low­ing the small­er com­pa­ny’s fail­ure to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER